Navigation Links
Results of the PROFI study reported at TCT 2011
Date:11/11/2011

SAN FRANCISCO, CA NOVEMBER 11, 2011 Results from the PROFI study indicate that the use of a proximal balloon occlusion in carotid artery stenting lead to fewer cerebral ischemic lesions a predictor of stroke than with the use of a filter. Trial results were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

Previous randomized trials have revealed a higher rate of stroke following carotid artery stenting when compared to surgical removal of plaque from the carotid artery. One of the reasons for this may be that the use of filters in carotid artery stenting allows plaque particles to travel to the brain. PROFI is the first randomized trial comparing proximal balloon occlusion with filter protection in patients undergoing carotid artery stenting

In the PROFI (Prevention of Cerebral Embolization by PROximal Balloon Occlusion Compared to FIlter Protection During Carotid Artery Stenting) trial, 62 patients undergoing carotid artery stenting with cerebral embolic protection for a ≥ 60 % symptomatic or ≥ 80% asymptomatic internal carotid artery stenosis were randomly assigned to proximal balloon occlusion or filter protection. The primary endpoint was the incidence of new cerebral ischemic lesions as assessed by diffusion weighted magnetic resonance imaging (DW-MRI). Secondary endpoints were the number and volume of new ischemic lesions and major adverse cardiovascular and cerebral events (MACCE).

The incidence rate of new cerebral ischemic lesions was 87.1%in the filter group, and 45.2% in the balloon group. The mean number of new cerebral ischemic lesions was 3.5 in the filter group and 1.0 in the balloon group. There were no significant differences in MACCE at 30 days between the two groups.

"In this single center, randomized trial in patients undergoing carotid artery stenting, the incidence, number, and volume of new cerebral ischemic lesions were significantly lower under proximal balloon protection than under filter protection," said Joachim Schofer, MD, Professor of Medicine, at the Medical Care Center, Professor Mathey, Professor Schofer, Hamburg University Cardiovascular Center.

"A larger randomized trial with clinical endpoints is needed to investigate whether this benefit translates into a reduced periprocedural stroke rate," said Dr. Schofer.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Results of the EVOLVE trial reported at TCT 2011
2. Results of the REMEDEE trial reported at TCT 2011
3. Results of the NEXT clinical trial Reported at TCT 2011
4. Results of the PEPCAD-DES trial reported at TCT 2011
5. Results of the STACCATO Trial reported at TCT 2011
6. Results of the DEB-AMI Trial reported at TCT 2011
7. Results of the RIFLE STEACS clinical trial reported at TCT 2011
8. Results of the PARTNER Trial Cohort B 2-year follow up presented at TCT 2011
9. Results of the PARTNER Trial Cohort A cost effectiveness analysis reported
10. Combination epigenetic therapy clinical trial results
11. Results of the PARIS registry Reported at TCT 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental ... Your Mouth?” (WIYM) campaign to inform dentists and patients about the safety issues related ... and prosthetic market in the U.S. is projected to reach $6.4 billion in 2018 ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today announced ... was set up in 2006 as a non-profit organization to unite pharmaceutical and ...
(Date:12/8/2016)... ... 08, 2016 , ... Healthcare is in flux. The GOP ... the mass media launching of story movements to highlight what's most unfair about ... experiences; such a movement can generate the network power to improve healthcare policies ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, an ... around the greater Phoenix metropolitan region, is announcing a charity event to provide ... the Homeless Youth Connection is to promote community awareness of the ongoing needs ...
(Date:12/7/2016)... ... 07, 2016 , ... DrugDev again demonstrated its dedication to reducing ... the early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department of Commerce. ... sides of the Atlantic with a mechanism to comply with EU data protection requirements ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016   TriNetX , the health research ... signed a membership agreement to join the ... new cures. The TriNetX network is ... patients globally, biopharmaceutical companies and contract research organizations ... design, site selection, patient recruitment, and collaborative research ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals International, ... VRX) ("Valeant") today announced positive results from a ... to assess the safety and efficacy of IDP-118 ... of plaque psoriasis. Within the ... moderate to severe psoriasis, IDP-118 showed statistical significance ...
(Date:12/8/2016)... 8, 2016  EIP Pharma, LLC ( www.eippharma.com ... for neflamapimod (previously code named VX-745), with the ... trials that demonstrated significant Alzheimer,s disease relevant pharmacological ... and Study 303 (6-week treatment) are the subject ... Disease (CTAD) scientific conference in San ...
Breaking Medicine Technology: